FSD Pharma and Celly Nutrition Corp. Schedule Virtual Securityholders Meeting

1.7 min readPublished On: October 23rd, 2023By

TORONTO — FSD Pharma, a noted biopharmaceutical company, and its partner Celly Nutrition Corp. have jointly announced a virtual meeting for FSD Pharma’s securityholders. Slated for November 20, 2023, at 1:00 p.m. Toronto time, this virtual gathering will take place via the AGM Connect platform. The main objective of this assembly is to approve the earlier mentioned plan of arrangement. This plan outlines FSD Pharma’s intention to allocate a portion of its Celly Nu stakes to selected FSD Pharma securityholders. Further information on this proposition is detailed in the management information circular.

A Closer Look at FSD Pharma Inc.

Positioned prominently in the biopharmaceutical landscape, FSD Pharma is steadfast in its mission to curate an innovative collection of assets and biotechnological solutions. These breakthrough solutions primarily target complex neurodegenerative, inflammatory, metabolic, and alcohol-related disorders. The company’s drug contenders are currently navigating through various developmental phases.

One of the spotlighted subsidiaries of FSD Pharma is Lucid Psycheceuticals Inc. Their lead compound, Lucid-MS, formerly known as Lucid-21-302, has become a focal point in their research spectrum. Preliminary studies suggest this patented chemical compound holds potential in halting and possibly reversing myelin degradation, a crucial aspect of multiple sclerosis. Beyond this, FSD Pharma is deeply engrossed in exploring UNBUZZD(TM) – a proprietary blend of natural elements, vitamins, and minerals. This mix aspires to support liver and brain health, with a particular emphasis on swiftly mitigating the effects of alcohol ingestion.

Supplementing FSD’s fiscal strength is another subsidiary, FSD Strategic Investments Inc., which emphasizes investments anchored by loans underpinned by residential or commercial assets.

Spotlight on PsychedelicNewsWire

PsychedelicNewsWire (PNW) emerges as a committed communication channel, casting light on the multifaceted world of psychedelics and the contemporary progress within the psychedelic sector. As part of the broader Dynamic Brand Portfolio @ IBN, PNW offers a wide array of services, from wire solutions to editorial syndication across over 5,000 platforms. With an experienced crew and a broad reach, PNW remains a vital partner for both nascent and established entities aspiring to carve a niche in an increasingly competitive arena.

About the Author: HCN News Team

The News Team at Highly Capitalized are some of the most experienced writers in cannabis and psychedelics business & finance. We cover capital markets, finance, branding, marketing and everything important in between. Most of all, we follow the money.

Share This Story, Choose Your Platform!